Australia · Delayed Price · Currency is AUD Radiopharm Theranostics Company Description
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.
The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Additionally, it is developing RAD301 and RAD302, which are Avβ6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic.
The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals.
The company was incorporated in 2021 and is based in Carlton, Australia.
| Country | Australia |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Riccardo Canevari |
Contact Details
Address: 62 Lygon Street Carlton, VIC 3053 Australia | |
| Phone | 61 3 9824 5254 |
| Website | radiopharmtheranostics.com |
Stock Details
| Ticker Symbol | RAD |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000181851 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Riccardo Canevari | MD, Chief Executive Officer and Director |
| Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Founder and Executive Chairman |
| Phillip Hains | Chief Financial Officer and Joint Company Secretary |
| Dr. Dimitris Voliotis M.D. | Chief Medical Officer |
| Hitesh Goel | Head of Project Management |
| Nathan Jong C.A. | Joint Company Secretary |